]>
IRCT20200522047542N1 IRCT 2020-08-04 Mashhad University of Medical Sciences Effect of Corton on olfactory dysfunction in COVID-19 patients Effect of inhaled corticosteroids in the treatment of anosmia in patients with COVID-19 2020-07-18 anticipated 70 Complete https://irct.ir/trial/48379 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization: Blocked Allocation Concealment: The researcher will be provided with closed envelopes, sequences produced in sealed, opaque and numbered envelopes, Blinding description: double-blinding of physician and participants. 1 Anosmia. Intervention 1: Intervention group: Inhaled Corticosteroid spray (0.05% Mometasone) twice daily for 4 weeks. Intervention 2: Control group: sodium chloride spray (0.65%) twice daily for 4 weeks. Yes - There is a plan to make this available What will be shared: Patient's follow up data When: 3 months after publishing the result To whom: Other researchers Conditions: for other researches Where to obtain: Dr. Mehdi Bakhshaei Dr.Masoomeh Hosseinpoor How to obtain: send an email and request Comments:
public Masoumeh Hosseinpour
Imam Reza Hospital, Ibn Sina Street ,and Ghaem Hospital, Ahmadabad Street
Masshad Iran (Islamic Republic of) 9176699311 +98 51 3840 9642 drmh2018@gmail.com Mashhad University of Medical Sciences scientific Masoumeh Hosseinpour
Imam Reza Hospital, Ibn Sina Street ,and Ghaem Hospital, Ahmadabad Street
Mashhad Iran (Islamic Republic of) 9176699311 +98 51 3840 9642 drmh2018@gmail.com Mashhad University of Medical Sciences Iran (Islamic Republic of) Patients with COVID-19 who have been referred or admitted to Qaem, Imam Reza, or Shariati Hospital diagnosed with a protocol defined by the World Health Organization. People who have not experienced any signs of reduced sense of smell and taste for at least 2 weeks before the onset of the first manifestation of Covid-19. People who were diagnosed with hyposmia or anosmia. 18 years 65 years Both People with certain underlying conditions (such as Parkinson's, Alzheimer's, severe nutritional disorders, acute rhinitis, acute catarrhal sinusitis, SICA syndrome (especially after radiation), nasal mucosal congestion, for example after rhinoplasty, olfactory nerve damage in trauma, etc., which are exposed to the reduction of the sense of smell independent of the coronavirus, as well as, people who experience other viral and bacterial infections simultaneously with COVID-19 People with a history of asthma and allergies are excluded Participants who refused to participate in follow-up measurements, provide data, or give consent considered withdrawn. R43.0 Anosmia Treatment - Drugs Placebo Intervention group: Inhaled Corticosteroid spray (0.05% Mometasone) twice daily for 4 weeks Control group: sodium chloride spray (0.65%) twice daily for 4 weeks Smell Sense. Timepoint: Time intervals: one week, two weeks, and one month after the intervention. Method of measurement: By VAS test. Mashhad University of Medical Sciences Approved 2020-07-17 National Ethics System In Biomedical Research School of Medicine, East Door of University Campus, Azadi Square Mashhad Razavi Khorasan Iran (Islamic Republic of)